These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31183814)

  • 1. VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era.
    Mizuta S; Kawata T; Kawabata H; Yamane N; Mononobe S; Komai T; Koba Y; Ukyo N; Tamekane A; Watanabe M
    Int J Hematol; 2019 Sep; 110(3):322-330. PubMed ID: 31183814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
    Courville EL; Yohe S; Shivers P; Linden MA
    Am J Clin Pathol; 2020 Jan; 153(2):221-228. PubMed ID: 31679012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
    Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double CD38
    Mykytiv V; Alwaheed A; Mohd Hashim NA
    Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
    Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
    Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 7. VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.
    Broijl A; de Jong ACM; van Duin M; Sonneveld P; Kühnau J; van der Velden VHJ
    Am J Clin Pathol; 2022 Apr; 157(4):494-497. PubMed ID: 34643211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.
    Sullivan HC; Gerner-Smidt C; Nooka AK; Arthur CM; Thompson L; Mener A; Patel SR; Yee M; Fasano RM; Josephson CD; Kaufman RM; Roback JD; Lonial S; Stowell SR
    Blood; 2017 Jun; 129(22):3033-3037. PubMed ID: 28373263
    [No Abstract]   [Full Text] [Related]  

  • 9. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein.
    Banham AH; Turley H; Pulford K; Gatter K; Mason DY
    J Clin Pathol; 1997 Jun; 50(6):485-9. PubMed ID: 9378814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen.
    Schneider U; van Lessen A; Huhn D; Serke S
    Br J Haematol; 1997 Apr; 97(1):56-64. PubMed ID: 9136942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.
    Hata H; Matsuzaki H; Matsuno F; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
    Clin Exp Immunol; 1994 May; 96(2):370-5. PubMed ID: 8187346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
    Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
    Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
    Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
    Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
    Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
    Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
    Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
    Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
    Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
    Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab.
    ElMaraashly AH; Tario J; Hillengass J; Qian YW
    Am J Clin Pathol; 2023 Nov; 160(5):524-532. PubMed ID: 37527544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.